本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

4D Pharma PLC

1.65
0.0000
成交量:- -
成交額:- -
市值:3,719.46萬
市盈率:-1.09
高:1.65
開:1.65
低:1.65
收:1.65
52周最高:1.65
52周最低:1.65
股本:2,254.22萬
流通股本:1,679.00萬
量比:- -
換手率:- -
股息:- -
股息率:- -
每股收益(TTM):-1.5072
每股收益(LYR):-1.5072
淨資產收益率:-89.48%
總資產收益率:-42.64%
市淨率:1.15
市盈率(LYR):-1.09

資料載入中...

2022/07/19

交易所摘牌聲明

25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2022/04/26

SEC問詢函

CORRESP [Cover] - Correspondence
2022/04/01

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/03/31

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/03/28

SEC問詢函

CORRESP [Cover] - Correspondence
2022/03/02

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/28

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/25

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/03

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/02/02

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/10/12

SEC問詢函

CORRESP [Cover] - Correspondence
2021/10/07

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/09/14

招股説明書

F-1 - Registration statement for certain foreign private issuers
2021/05/21

SEC問詢函

CORRESP [Cover] - Correspondence
2021/05/21

SEC問詢函

CORRESP [Cover] - Correspondence
2021/04/30

[修訂]年度報告

20-F/A [Amend] - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/04/30

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/04/23

招股説明書

F-1 - Registration statement for certain foreign private issuers
2021/04/12

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/04/02

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]